PMC9444693_01
A Chest radiograph and B CT scan at admission. C The most recent chest radiograph (July, 2021)
12185_2022_3449_Fig1_HTML.jpg
PMC9444693_01_12185_2022_3449_Fig1_HTML.jpg
Fig1
Chest radiography and computed tomography (CT) revealed pericardial and bilateral pleural effusion (Fig. 1A, B). Imatinib was started in December 2020, and the DMR for CML treatment was maintained in April 2022, without relapse of PEL-LL (Fig. 1C).
Cytopathological and immunophenotypic examination of pericardial effusion cell blocks. A Hematoxylin-eosin staining B CD 20 C Epstein-Barr encoding region
12185_2022_3449_Fig2_HTML.jpg
PMC9444693_01_12185_2022_3449_Fig2_HTML.jpg
Fig2
Cytopathological examination showed numerous large atypical lymphoid cells, which were immunohistochemically positive for CD20, Epstein-Barr encoding region (EBER), and the kappa chain, and mildly positive for TP53.The Ki-67 proliferation index was high (Fig. 2A-C).